These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38368871)

  • 1. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2- Breast Cancer: Impact of Tumor Ki67 and ER Status.
    Akdag G; Yildirim S; Dogan A; Yuksel Yasar Z; Bal H; Kinikoglu O; Oksuz S; Ozkerim U; Tunbekici S; Yildiz HS; Turkoglu E; Alan O; Coban Kokten S; Isik D; Sever ON; Odabas H; Yildirim ME; Turan N
    Chemotherapy; 2024 Feb; ():. PubMed ID: 38368871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis.
    Zhang S; Liu Y; Liu X; Liu Y; Zhang J
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67.
    Boughey JC; Hoskin TL; Goetz MP
    Ann Surg Oncol; 2022 Sep; 29(9):5747-5756. PubMed ID: 35569077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer.
    Moldoveanu D; Hoskin TL; Day CN; Schulze AK; Goetz MP; Boughey JC
    Breast Cancer Res Treat; 2024 Feb; 203(3):419-428. PubMed ID: 37878154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in cN0 Breast Cancer: Impact of HER2-Positive Status on Survival.
    Alors-Ruiz J; Sanz-Viedma S; Fernández-Garcia FJ; Sendra-Portero F
    Eur J Breast Health; 2024 Apr; 20(2):94-101. PubMed ID: 38571688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Correlation of Rate of Pathological Complete Response and Outcome in Post Neoadjuvant Chemotherapy Setting and Molecular Subtypes of Breast Cancer.
    Omair A; Alkushi A; Alamri G; Almojel T; Alsadun S; Masuadi E; Arabi H; Mohamed AE; Abulkhair OA
    Cureus; 2023 Apr; 15(4):e37449. PubMed ID: 37181967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
    Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
    Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.
    Cabrera-Galeana P; Muñoz-Montaño W; Lara-Medina F; Alvarado-Miranda A; Pérez-Sánchez V; Villarreal-Garza C; Quintero RM; Porras-Reyes F; Bargallo-Rocha E; Del Carmen I; Mohar A; Arrieta O
    Oncologist; 2018 Jun; 23(6):670-678. PubMed ID: 29490940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
    Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies.
    Poterala JE; Havighurst T; Braun Wisinski K
    Clin Breast Cancer; 2022 Aug; 22(6):611-618. PubMed ID: 35676188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a novel nomogram-based online tool to predict axillary status after neoadjuvant chemotherapy in cN+ breast cancer: A multicentre study on 1,950 patients.
    Corsi F; Albasini S; Sorrentino L; Armatura G; Carolla C; Chiappa C; Combi F; Curcio A; Della Valle A; Ferrari G; Gasparri ML; Gentilini O; Ghilli M; Listorti C; Mancini S; Marinello P; Meani F; Mele S; Pertusati A; Roncella M; Rovera F; Sgarella A; Tazzioli G; Tognali D; Folli S
    Breast; 2021 Dec; 60():131-137. PubMed ID: 34624755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
    Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
    BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings.
    Hashmi AA; Bukhari U; Najam J; Dowlah T; Ali AH; Diwan MA; Anjali F; Sham S; Zia S; Irfan M
    Cureus; 2023 Jun; 15(6):e40066. PubMed ID: 37425505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.